J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025

---
J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025
Vote:
0 0
Previous Benchmark ads in the Kantar Digital Creative Effectiveness Awards for APAC are built on meaningful moments
Next UOB and Accenture collaborate to transform customer experience using advanced technologies including GenAI

Related News

J INTS BIO, Oral TKI 'JIN-A04', poster presentation of HER2 exon20 insertion mutation in NSCLC

Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC

Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting

Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting

Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207, a 4th generation EGFR TKI

J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001' - Enhancing Radiation and Chemotherapy Efficacy

menu
menu